Croda International Plc: Investors Paying Above Intrinsic Value?

Croda International Plc (LON:CRDA), a British specialty chemicals company, has been a darling of the investment community, with its shares soaring by 1,909.90% since its IPO. However, a recent analysis suggests that the stock may be overvalued, with its intrinsic value estimated to be 24% below its current share price. This article explores the factors contributing to Croda's stock performance and the implications for investors.

Croda's earnings and revenue growth have been a significant driver of its stock performance. The company has consistently delivered strong financial results, with earnings per share (EPS) and revenue growth rates contributing to its share price appreciation. For instance, in the six months ended June 2023, Croda reported EPS of £0.63, up from £0.39 in the same period in 2022, representing a growth rate of 61.5%. Similarly, revenue grew by 14.3% year-over-year to £1.69 billion.

Looking ahead, analysts expect Croda's earnings and revenue growth to continue. The consensus EPS growth rate is forecasted at 14.4% per annum, while revenue growth is expected to be 5.5% per annum. This positive outlook is reflected in the stock price, which has increased by 34.9% based on analyst estimates.

However, it is essential to note that Croda's stock performance is not solely driven by earnings and revenue growth. Other factors, such as market conditions, investor sentiment, and the company's strategic initiatives, also play a role in its share price movements.

Croda's strategic decisions, such as the acquisition of Solus Biotech Co., Ltd., have had an impact on its intrinsic value and share price. According to an analysis from August 12, 2024, Croda's intrinsic value is potentially 24% below its share price, indicating that the market may not fully appreciate the value of the company's strategic moves. However, it is essential to note that the intrinsic value estimate is subject to change, and the actual impact of the acquisition on Croda's intrinsic value and share price may vary over time.



In conclusion, while Croda International Plc has delivered impressive earnings and revenue growth, and analysts expect this trend to continue, the stock may be overvalued based on its intrinsic value. Investors should carefully consider the company's strategic initiatives and market conditions before making investment decisions. As always, it is essential to conduct thorough research and consult with a financial advisor before investing in any company.